Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$12.90 -1.62%

-$0.22 today

Market cap
$1.95B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 2.32M

Average 2.47M

BHVN Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Biohaven Ltd.NYSE: BHVN

Retained Earnings · Q2 FY2026 · quarter ended Jun 2026

Retained earnings remains negative

Q2 FY2026 retained earnings was -$2.35B, compared with -$1.77B a year earlier.

Context

  • Retained earnings amounted to 634.5% of total assets at the end of Q2 FY2026, up 313.7 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -33.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$2.35B-6.2% QoQ
Last fiscal yearDec 2025
-$2.08B-54.9% YoY
Year agoJun 2025
-$1.77B-33.2% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.2%——
1 year-54.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(2.08B) USD
Year-over-year change
-54.9%

Retained Earnings vs competitors

How BHVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -33.2% is the 5th highest of 11, against a peer median of -38.8%.
  • Retained earnings amounts to 634.5% of total assets for BHVN, versus a peer median of 178.3%.
BHVN Competitors
Retained Earnings for BHVN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABCLAbCellera Biologics Inc.Sep 2026-$168.83M USD-722.1%—11.3%
SIONSionna Therapeutics, Inc.Mar 2026-$283.13M USD-43.3%—92.8%
XERSXeris Biopharma Holdings, Inc.Mar 2026-$669.07M USD+1.8%—170.7%
PHVSPharvaris N.V.Sep 2026-€716.58M EUR-34.6%—242.9%
IMCRImmunocore Holdings plcMar 2026-$818.3M USD-3.5%—76.3%
ZBIOZenas BioPharma, Inc.Mar 2026-$846.12M USD-101.0%—113.2%
IMNMImmunome, Inc.Sep 2026-$940.91M USD-42.9%—186.1%
VERAVera Therapeutics, Inc.Jun 2026-$991.37M USD-68.2%—186.0%
CLDXCelldex Therapeutics, Inc.Sep 2026-$2.04B USD-17.8%—283.0%
BHVNBiohaven Ltd.Jun 2026-$2.35B USD-33.2%—634.5%
NTLAIntellia Therapeutics, Inc.Mar 2026-$2.69B USD-17.2%—354.0%
Peer median (excluding BHVN) —-38.8%—178.3%

Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents76.06M204.88M248.4M99.13M229.96M
Short-term Investments0260.46M133.42M386.86M89.18M
Net Receivables046.14M13.25M2.6M0
Inventory00000
Other Current Assets12.03M54.54M12.13M508K2.17M
Total Current Assets94.82M586.97M442.45M538.47M368.33M
Property, Plant & Equipment (Net)17.68M52.44M48.58M53.71M15.96M
Goodwill1.39M1.39M1.39M1.39M1.39M
Intangible Assets18.95M18.4M18.4M18.4M18.4M
Long-term Investments6M0000
Tax Assets00000
Other Non-current Assets3.22M2.59M2.4M3.13M47.36M
Total Non-current Assets47.24M74.82M70.77M76.64M83.12M
Total Assets142.06M661.78M513.21M615.11M451.45M
Account Payables4.78M10.7M15.58M18.03M11.64M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities9.54M14.6M35.7M84.71M59.49M
Total Current Liabilities41.94M90.02M55.42M154.23M115.93M
Long-term Debt0000238.9M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities2.64M2.41M2.25M4.66M4.58M
Total Non-current Liabilities5.44M32.99M29.81M37.45M283.44M
Total Liabilities47.37M123.01M85.24M191.67M399.38M
Common Stock34.69M615.74M887.53M1.66B1.93B
Retained Earnings0(91.12M)(499.29M)(1.35B)(2.08B)
Accumulated OCI0284K(65K)79K8.35M
Other Stockholders Equity00000
Minority Interest60M0000
Total Equity94.69M538.77M427.98M423.44M52.07M
Total Debt3.24M33.6M30.88M36.58M284.61M
Net Debt(72.82M)(171.28M)(217.53M)(62.55M)54.66M

Biohaven Ltd.

NYSE:BHVN

Intrinsic Alpha fair value

Locked

Current Price

$12.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.